Cargando…
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
BACKGROUND: At a time when programs were struggling to design effective regimens for the treatment of multidrug-resistant tuberculosis (MDR-TB), the marketing authorization of bedaquiline and delamanid was a critical development in the MDR-TB treatment landscape. However, despite their availability...
Autores principales: | Khan, Uzma, Huerga, Helena, Khan, Aamir J., Mitnick, Carole D., Hewison, Catherine, Varaine, Francis, Bastard, Mathieu, Rich, Michael, Franke, Molly F., Atwood, Sidney, Khan, Palwasha Y., Seung, Kwonjune J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701145/ https://www.ncbi.nlm.nih.gov/pubmed/31429722 http://dx.doi.org/10.1186/s12879-019-4378-4 |
Ejemplares similares
-
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the
endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022) -
Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023) -
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study
por: Franke, Molly F., et al.
Publicado: (2021) -
Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017) -
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs( )
por: Huerga, Helena, et al.
Publicado: (2022)